Formatech fills for Phase I Cellceutix study

Drug formulator Formatech of Andover, MA, will prep Kevetrin, a candidate for the treatment of drug-resistant cancers, for a Cellceutix Phase I study. The small-molecule substance will take the form of a lyophilized powder for reconstitution in saline solution. Terms were not disclosed. Formatech also runs the Fillanthropy program, through which Tracon Pharma recently received an aseptic fill and finish donation for one lot of its TRC102 cancer treatment candidate. Cellceutix release | Tracon announcement